HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AM6545

structure in first source

Also Known As:

5-(4-(4-cyanobut-1-ynyl)phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide

Networked: 10 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - AM6545: 10
  - Oxazines: 9
    - Morpholines: 6
      - AM6545: 10

Experts

1.	Vemuri, Kiran: 4 articles (02/2021 - 10/2015)
2.	Makriyannis, Alexandros: 3 articles (02/2021 - 10/2017)
3.	Makriyannis, A: 3 articles (12/2018 - 09/2010)
4.	Vemuri, V K: 3 articles (12/2018 - 09/2010)
5.	Aldawsari, Hibah M: 2 articles (02/2021 - 10/2020)
6.	Eid, Basma G: 2 articles (02/2021 - 10/2020)
7.	El-Bassossy, Hany M: 2 articles (02/2021 - 10/2020)
8.	Hanafy, Abeer: 2 articles (02/2021 - 10/2020)
9.	Neamatallah, Thikryat: 2 articles (02/2021 - 10/2020)
10.	Bedard, H: 2 articles (10/2010 - 09/2010)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/06/2021 - "This study investigated the effects of two neutral CB1 receptor antagonists, AM6545 and AM4113, on nephropathy associated with metabolic syndrome (MetS). " 11/03/2023 - "Effects of the CB1 receptor antagonists AM6545 and AM4113 on metabolic syndrome-induced prostatic hyperplasia in rats." 02/06/2021 - "Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome." 10/29/2020 - "Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome."
2.	Insulin Resistance 01/01/2018 - "Taken together, the current study indicates that AM6545 induced a comprehensive metabolic improvement in the MSG mice including counteracting the hypometabolic and hypothalamic obesity, and improving the accompanied dyslipidemia and insulin resistance. " 10/29/2020 - "Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome."
3.	Dyslipidemias (Dyslipidemia) 01/01/2018 - "Taken together, the current study indicates that AM6545 induced a comprehensive metabolic improvement in the MSG mice including counteracting the hypometabolic and hypothalamic obesity, and improving the accompanied dyslipidemia and insulin resistance. " 01/01/2018 - "3-Week AM6545 treatment dose-dependently decreased the body weight, intraperitoneal fat mass, and rectified the accompanied dyslipidemia include elevated serum triglyceride, total cholesterol, free fatty acids, and lowered LDLc level. "
4.	Obesity 01/01/2018 - "Taken together, the current study indicates that AM6545 induced a comprehensive metabolic improvement in the MSG mice including counteracting the hypometabolic and hypothalamic obesity, and improving the accompanied dyslipidemia and insulin resistance. " 01/01/2018 - "Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice." 01/01/2018 - "Effect of peripheral cannabinoid receptor 1 (CB1R) blockade by AM6545 in the monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity was observed, and the impact on intraperitoneal adipose tissue and adipokines was investigated. "
5.	Fibrosis (Cirrhosis) 10/01/2015 - "Genetic deletion or pharmacological inhibition of CB1 receptors with a peripheral CB1 antagonist AM6545 markedly attenuated or delayed the lung inflammation and fibrosis and increased animal survival. " 02/06/2021 - "In conclusion, AM6545 and AM4113, possess reno-protective effects by interfering with TGFβ1-mediated renal inflammation and fibrosis, via peripheral action." 02/06/2021 - "Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome." 10/01/2017 - "Renal function and structure, podocyte proteins and markers of both fibrosis and inflammation were studied in streptozotocin-induced diabetic mice treated for 14 weeks with vehicle, AM6545, AM1241 and AM6545-AM1241. " 12/01/2018 - "Single treatment with either AM6545 or perindopril significantly reduced progression of albuminuria, down-regulation of nephrin and podocin, inflammation and expression of markers of fibrosis. "

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	AM4113
3.	Sodium Glutamate (Accent)
4.	Adipokines
5.	Cannabinoid Receptors (Cannabinoid Receptor)
6.	Streptozocin (Streptozotocin)
7.	Albumins
8.	nephrin
9.	Cannabinoid Receptor Antagonists
10.	Perindopril

Related Therapies and Procedures

1.	Therapeutics